Pharos I Bio Joins Lilly's AI Drug Discovery Platform
Proprietary AI Platform 'Chemiverse'
Connected to Lilly's AI and Big Data Infrastructure
Pharos I Bio, an artificial intelligence (AI) drug discovery company, announced on June 9 that it has signed an agreement to join the AI drug discovery platform 'Lilly Tunelab' operated by global pharmaceutical firm Eli Lilly.
Lilly Tunelab is an AI and machine learning (ML) collaboration program within 'Catalyze360,' Eli Lilly's open innovation platform. Based on federated learning technology, it is designed to allow pharmaceutical and biotech companies to participate in developing AI models without disclosing their data externally.
Pharos I Bio plans to leverage its accumulated experience in candidate discovery and clinical development, gained through its proprietary AI drug discovery platform Chemiverse, and connect this expertise to Eli Lilly’s AI and ML drug development environment. The company will review the physicochemical properties, druggability, and development potential of its key pipelines through this collaboration.
The company expects that this partnership will reduce the costs associated with securing large-scale data and AI infrastructure, while also verifying the global competitiveness of its Chemiverse-based candidates and development strategies. Moving forward, Pharos I Bio aims to pursue joint research and technology commercialization opportunities with global pharmaceutical companies, building upon its collaboration with Eli Lilly.
Hot Picks Today
"Bought Raw Materials at 1,500 Won, Selling at 1,300 Won"—Exchange Rate Plunge Casts a Shadow as Export Giants Face Third-Quarter Alarm
- "An Insult to All Women": Female Athletes Outraged Over Ad with 37 Million Views in Four Days
- U.S. 10-Year Treasury Yield Surges as Oil Prices Climb...Tops Psychological 5% Threshold (Comprehensive 2nd Report)
- "Hobbies Turned into Obsessions: The Trend Among Young People Who Feel Guilty Relaxing in Front of the TV"
- "Weight Dropped Rapidly... Anyone Can Get It Easily": Why a Woman in Her 20s Quit Mountzaro After Losing 6kg in a Month
A representative from Pharos I Bio commented, “This marks the starting point for linking our expertise in candidate discovery and clinical development, accumulated through Chemiverse, with the AI and ML collaboration framework of global big pharma. We will continue to expand opportunities for global AI drug discovery collaborations.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
